Edgecortix is a biotechnology company that is developing a new class of drugs to treat cancer. The company was founded in 2018 by Dr. David Weinstock and Dr. Nathanael Gray. Edgecortix's drugs target a specific protein that is involved in the growth and survival of cancer cells. The company's goal is to develop drugs that are more effective and less toxic than current cancer treatments. Edgecortix has received funding from investors such as Polaris Partners and MPM Capital.